FEATURE: Nothing to Fear But Fear Itself: How FDA and Pharma Will Make Microarrays Mainstream | GenomeWeb

This is the second in a two-part series that examines how--or whether--drug companies and the US Food and Drug Administration can use microarray data in the drug-approval process. Today's installment explores how the FDA and pharma firms plan to usher the technology into the mainstream.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.